HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX)

HC Wainwright reaffirmed their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research note published on Monday morning, Benzinga reports. The brokerage currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.67) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.52) EPS.

Immix Biopharma Trading Down 3.1 %

NASDAQ IMMX opened at $2.21 on Monday. Immix Biopharma has a 12 month low of $1.75 and a 12 month high of $7.75. The stock has a market cap of $58.37 million, a PE ratio of -2.38 and a beta of 0.17. The stock’s 50 day moving average is $2.10 and its 200 day moving average is $2.46.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Monday, August 12th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. On average, analysts forecast that Immix Biopharma will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. OLD National Bancorp IN purchased a new stake in Immix Biopharma during the fourth quarter valued at $69,000. Jump Financial LLC bought a new position in shares of Immix Biopharma in the 4th quarter valued at about $128,000. Tritonpoint Wealth LLC purchased a new position in Immix Biopharma in the first quarter worth about $75,000. Invst LLC bought a new stake in Immix Biopharma during the second quarter worth approximately $57,000. Finally, Tocqueville Asset Management L.P. raised its position in Immix Biopharma by 89.0% during the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock valued at $116,000 after purchasing an additional 17,800 shares during the period. 11.26% of the stock is currently owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.